2-Methyl-2-(2,2,2-trifluoroethylamino)propan-1-ol | 1094071-78-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Methyl-2-(2,2,2-trifluoroethylamino)propan-1-ol
• CAS: 1094071-78-9
• 化学式: C₆H₁₂F₃NO
• 分子量: 171.163
• InChiKey: LDAPBILBGQQNOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (5-(6-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-ylamino)isothiazol-3-yl)methyl methanesulfonate 、 2-Methyl-2-(2,2,2-trifluoroethylamino)propan-1-ol 在 sodium hydride 、 sodium iodide 、 盐酸 作用下， 以 四氢呋喃 、 mineral oil 、 1,4-二氧六环 、 甲醇 为溶剂， 反应 8.67h， 以59%的产率得到2-methyl-2-[[[5-[[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-isothiazolyl]methyl](2,2,2-trifluoroethyl)amino]-1-propanol hydrochloride
  参考文献：
  名称：

  Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure

  摘要：

  Aurora kinases are cell cycle regulated serine/threonine kinases that have been linked to cancer Compound 1 was identified as a potent Aurora inhibitor but lacked oral bioavailability Optimization of 1 led to the discovery of a series of fluoroamine and deuterated analogues, exemplified by compound 25, with an improved pharmacokinetic profile We found that blocking oxidative metabolism at the benzylic position and decreasing the basicity of the amine are important to obtaining compounds with good biological profiles and oral bioavailability

  DOI：

  10.1021/jm1010995

文献信息

• Aurora Kinase Inhibitors Based on the Imidazo[1,2-<i>a</i>]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure
  作者：Angela D. Kerekes、Sara J. Esposite、Ronald J. Doll、Jayaram R. Tagat、Tao Yu、Yushi Xiao、Yonglian Zhang、Dan B. Prelusky、Seema Tevar、Kimberly Gray、Gaby A. Terracina、Suining Lee、Jennifer Jones、Ming Liu、Andrea D. Basso、Elizabeth B. Smith

  DOI：10.1021/jm1010995

  日期：2011.1.13

  Aurora kinases are cell cycle regulated serine/threonine kinases that have been linked to cancer Compound 1 was identified as a potent Aurora inhibitor but lacked oral bioavailability Optimization of 1 led to the discovery of a series of fluoroamine and deuterated analogues, exemplified by compound 25, with an improved pharmacokinetic profile We found that blocking oxidative metabolism at the benzylic position and decreasing the basicity of the amine are important to obtaining compounds with good biological profiles and oral bioavailability